NewGLAB PharmaLTD Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yoon-Hwa Ko

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Geen updates

Recent updates

The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?

Dec 22

CEO

Yoon-Hwa Ko (55 yo)

no data

Tenure

Yoon-Hwa Ko serves as the Co-Chief Executive Officer of NewGLAB Pharma CO.,LTD (formerly known as NewGLAB CO.,LTD) (formerly known as HDPRO Co., Ltd.)

NewGLAB PharmaLTD Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Recent updates

NewGLAB Pharma CO.,LTD announced that it has received KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investors

NewGLAB Pharma CO.,LTD announced that it expects to receive KRW 6.835 billion in funding from Namhwa Corporation, SLP Co. Ltd. and other investors

Full year 2022 earnings released: ₩2,201 loss per share (vs ₩1,662 loss in FY 2021)

Now 25% undervalued

NewGLAB Pharma CO.,LTD announced that it has received KRW 25 billion in funding from DB Financial Investment Co.,Ltd., Investment Arm

NewGLAB CO.,LTD announced that it has received KRW 9.23 billion in funding

Full year 2020 earnings released: ₩834 loss per share (vs ₩190 loss in FY 2019)

NewGLAB CO.,LTD announced that it expects to receive KRW 9.23 billion in funding

New 90-day low: ₩10,900

New 90-day low: ₩11,850

The NewGLABLTD (KOSDAQ:214870) Share Price Has Gained 274%, So Why Not Pay It Some Attention?

New 90-day low: ₩12,750

NewGLAB CO.,LTD announced that it expects to receive KRW 35 billion in funding from DB Financial Investment Co.,Ltd., Investment Arm

New 90-day high - ₩15,900

CEO

Tenure